



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
25.09.2019 Bulletin 2019/39

(45) Date of publication and mention
of the grant of the patent:
10.04.2019 Bulletin 2019/15

(21) Application number: **13830158.5**

(22) Date of filing: **27.12.2013**

(51) Int Cl.:
A61K 9/08 ^(2006.01) **A61K 47/10** ^(2017.01)
A61K 31/196 ^(2006.01) **A61P 29/00** ^(2006.01)

(86) International application number:
PCT/IN2013/000805

(87) International publication number:
WO 2014/102824 (03.07.2014 Gazette 2014/27)

(54) **DICLOFENAC COMPOSITION**
DICLOFENACZUSAMMENSETZUNG
COMPOSITION DE DICLOFÉNAC

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **28.12.2012 IN 3704MU2012**

(43) Date of publication of application:
04.11.2015 Bulletin 2015/45

(73) Proprietor: **Themis Medicare Limited**
Goregaon (W), Mumbai 400 104 (IN)

(72) Inventors:
• **PATEL, Dinesh Shantilal**
Mumbai 400 104
Maharashtra (IN)
• **PATEL, Sachin Dinesh**
Mumbai 400 104
Maharashtra (IN)
• **KURANI, Shashikant Prabhudas**
Mumbai 400 104
Maharashtra (IN)
• **PATEL, Madhavlal Govindlal**
Mumbai 400 104
Maharashtra (IN)

(74) Representative: **HGF Limited**
1 City Walk
Leeds LS11 9DX (GB)

(56) References cited:
WO-A2-2005/027977 WO-A2-2006/126214
US-A1- 2008 153 914

- **M. MANCONI ET AL: "Penetration enhancer-containing vesicles: Composition dependence of structural features and skin penetration ability", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 82, no. 2, 1 October 2012 (2012-10-01), pages 352-359, XP055115170, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2012.06.015**
- **"Final Report - Measurement of Pain Sensitivity (Threshold) at Aquadol Injection Site in Wistar Rats by Intramuscular Route", 25 June 2014 (2014-06-25), Spira Labs Limited**
- **NICOLL LESLIE H ET AL: "Intramuscular injection: an integrative research review and guideline for evidence-based practice.", APPLIED NURSING RESEARCH : ANRAUG 2002, vol. 15, no. 3, August 2002 (2002-08), pages 149-162, ISSN: 0897-1897**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- "Propylene Glycol" In: "Handbook of Pharmaceutical Excipients", 2009 pages 592-594,
- "Polyethylene Glycol" In: "Handbook of Pharmaceutical Excipients", 2009 pages 517-522,
- Aparicio RM et al.: "In vitro studies of the hemolytic activity of microemulsions in human erythrocytes", ScienceDirect Journal of Pharmaceutical and Biomedical Analysis, vol. 39, no. 5 28 July 2005 (2005-07-28), Retrieved from the Internet:
URL:<http://www.sciencedirect.com/science/article/pii/S0731708505004139> [retrieved on 2016-06-17]
- Mottu F et al.: "Comparative Hemolytic Activity of Undiluted Organic Water-Miscible Solvents for Intravenous and Intra-Arterial Injection", journal.pda.org PDA Journal of Pharmaceutical Science and Technology, vol. 55, no. 1 2001, Retrieved from the Internet:
URL:http://journal.pda.org/content/55/1/16.abstract?ijkey=e8b62278383a2566dddc69d24ac9947b6f94e92bb&keytype2=tf_ipsecsha [retrieved on 2016-06-20]

- "Glycofurol" In: "Handbook of Pharmaceutical Excipients", 2009 pages 297-298,

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification